BioSpace News Archive

On the heels of its April 7 launch announcement, Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced that James R. Tobin has been appointed to the company’s Board of Directors.

ExThera Medical announced the release of preliminary clinical study data demonstrating significantly improved survival rates among critically ill COVID-19 patients when treated with the Seraph® 100 Microbind® Affinity Blood Filter compared to contemporaneous controls.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for Psilocybin to treat moderate to severe traumatic brain injury (“TBI”).

With Lyme disease season emerging and the COVID-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5.

A recently published study from an EU-funded project[i] demonstrates that the prebiotic enrichment of infant formula milk with BENEO’s oligofructose-enriched inulin reduces the duration of infections in the first year of a baby’s life.

Results of a survey co-sponsored by PMD Alliance and Adamas showed the need for education in the Parkinson’s community about OFF time and dyskinesia

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol ® Cyclo™ in Niemann-Pick Type C1 Patient enrollment on track to commence in Q2 2021 Global clinical protocol agreed with US Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercialization of the Guardant360® CDx blood test as a companion diagnostic for Enhertu® (fam-trastuzumab deruxtecan-nxki)

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the company will release first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of market.

Incyte announced that it will present at the Bank of America Securities Virtual 2021 Healthcare Conference on Thursday, May 13, 2021 at 12:30 p.m. ET.